NATURAL ANTI-OXIDANT SUPPLEMENTATION PRIOR TO INFERTILITY TREATMENT RESULTS IN EXCELLENT CLINICAL OUTCOMES FOR INFERTILITY PATIENTS WITH PRIOR IVF FAILURES.
NATURAL ANTI-OXIDANT SUPPLEMENTATION PRIOR TO INFERTILITY TREATMENT RESULTS IN EXCELLENT CLINICAL OUTCOMES FOR INFERTILITY PATIENTS WITH PRIOR IVF FAILURES. L. A. Munkwitz, W. B. Schoolcraft, M. Katz-Jaffe. Colorado Center for Reproductive Medicine, Lone Tree, CO.
OBJECTIVE: Oxidative stress is known to be a significant contributor to ovarian dysfunction and subsequent poor oocyte quality. The aim of this study was to examine the clinical benefit of supplementation with a natural anti-oxidant prior to ovarian stimulation and in vitro fertilization (IVF) for women with prior IVF failures.
DESIGN: Prospective study.
MATERIALS AND METHODS: Infertility patients presenting with R1 prior failed IVF cycle, maternal age <45 years and no severe male factor infertility were consented into the study (n1⁄4124). Female patients (mean age 1⁄4 37.8 3.8 years) were instructed to take 600mg of natural Euterpe oleracea three times a day for 8-12 weeks prior to routine ovarian stimulation. The Euterpe oleracea administered in this study was biochemically tested to confirm high anti-oxidant activity. IVF cycle and FET outcomes were analyzed for each patient comparing their most recent IVF cycle without as a control to their IVF cycle with anti-oxidant supplementation using the Student’s paired t-test and Fisher’s exact test, with significance at P<0.05.
RESULTS: The vast majority of the women presented with normal ovarian reserve (mean AFC1⁄418.810; AMH1⁄43.93.3ng/ml; D3 FSH1⁄47.52.7IU/L) and they all experienced R1 failed IVF cycle prior to the study. Following anti-oxidant supplementation only one patient had her cycle cancelled (0.8%), four patients had no embryos develop to the blasto- cyst stage (3.2%) and 25 patients had all aneuploid blastocysts (20.2%). Of the remaining 93 patients with euploid blastocysts (54% overall euploidy) there were significant improvements in comparison to the control cycle in oocyte yield (19.6 9.7 vs. 14.57.6; P1⁄40.0001) and in number of fertilized zygotes (11.16.0 vs. 7.95.1; P1⁄40.0003). Outcomes after transfer of euploid blastocyst (mean 1.6) for these 93 patients all with prior IVF failure were excellent: 84.9% clinical pregnancy with fetal heart tone, 6.3% miscar- riage rate and 79.6% live birth rate.
CONCLUSIONS: Preliminary results indicate improvements in clinical IVF outcomes following the supplementation of a highly active anti-oxidant prior to ovarian stimulation. The restoration of the balance between oxidants and anti-oxidants in the ovary during the early stages of oocyte development may account for the clinical improvements observed. Ongoing investigations into the factors associated with oocyte quality will contribute to improved success for women with a history of IVF failures.